Cizzle Biotechnology Holdings plc (LSE: CIZ), a UK-based developer of diagnostic tests for early-stage cancer, announce on Wednesday that it has been granted patent protection in Canada covering methods to measure the CIZ1B lung cancer biomarker.

Titled 'Use of a fibrinogen capture agent to detect a CIZ1B variant', the patent protects a proprietary two-step test format developed at the University of York. Intellectual property strengthens Cizzle Biotechnology's global patent portfolio, complementing existing protection in the United States and Europe, with a further United States patent application expected to be granted in due course.

This technology is licensed to Cizzle Bio Inc for use in North America and the Caribbean, enhancing its position in commercialising the CIZ1B test through partnerships with specialist clinical laboratories and hospitals. Canadian patent grant reinforces the Company's ability to execute its international licensing-led commercial strategy.

The CIZ1B biomarker, discovered by Professor Dawn Coverley and her research team at the University of York, is strongly associated with early-stage lung cancer and can be detected through a non-invasive blood test. Cizzle Biotechnology continues to pursue partnerships in the UK and Europe, including with NHS-accredited facilities, aligned with healthcare initiatives focused on earlier cancer diagnosis.